293 related articles for article (PubMed ID: 16622114)
1. Assessing risk: does this patient have prostate cancer?
Carter HB
J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
[No Abstract] [Full Text] [Related]
2. [Detection of prostate cancer: yes or no?].
Van Cangh PJ
Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
[No Abstract] [Full Text] [Related]
3. Screening for prostate cancer - will we ever know?
Adolfsson J
Acta Oncol; 2010 Apr; 49(3):275-7. PubMed ID: 20397764
[No Abstract] [Full Text] [Related]
4. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
5. Prostate cancer: is the PSA test the answer?
Berlin B
N J Med; 1998 Mar; 95(3):53-5. PubMed ID: 16013148
[No Abstract] [Full Text] [Related]
6. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis of prostate cancer].
Strittmatter F
MMW Fortschr Med; 2010 May; 152(19):40-2. PubMed ID: 20557001
[No Abstract] [Full Text] [Related]
8. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
[TBL] [Abstract][Full Text] [Related]
9. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
Johnson L
Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
[No Abstract] [Full Text] [Related]
10. Efficacy vs effectiveness in prostate-specific antigen screening.
Albertsen PC
J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
[No Abstract] [Full Text] [Related]
11. What is the value of screening for prostate cancer in the US?
Albertsen PC
Nat Clin Pract Oncol; 2005 Nov; 2(11):536-7. PubMed ID: 16270077
[No Abstract] [Full Text] [Related]
12. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Ansari MS
J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
[No Abstract] [Full Text] [Related]
13. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
14. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
D'Amico AV
J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
[No Abstract] [Full Text] [Related]
15. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Thompson IM; Ankerst DP; Etzioni R; Wang T
J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
[No Abstract] [Full Text] [Related]
16. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
17. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
Belpomme D; Irigaray P
J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
[No Abstract] [Full Text] [Related]
18. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
Medvedev VL
Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
[No Abstract] [Full Text] [Related]
19. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.
Nam RK; Kattan MW; Chin JL; Trachtenberg J; Singal R; Rendon R; Klotz LH; Sugar L; Sherman C; Izawa J; Bell D; Stanimirovic A; Venkateswaran V; Diamandis EP; Yu C; Loblaw DA; Narod SA
J Clin Oncol; 2011 Aug; 29(22):2959-64. PubMed ID: 21690464
[TBL] [Abstract][Full Text] [Related]
20. The PSA era is not over for prostate cancer.
Catalona WJ; Loeb S
Eur Urol; 2005 Oct; 48(4):541-5. PubMed ID: 16139417
[No Abstract] [Full Text] [Related]
[Next] [New Search]
